Big News: FounderDating is joining OneVest to build the largest community for entrepreneurs. Details here
Latest Notifications
You have no recent recommendations.
Name
Title
 
MiniBio
FOLLOW
Title
 Followers
FOLLOW TOPIC

Question goes here

1,300 Followers

  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur
  • Name
    Entrepreneur

What are the sub-licensing fees to be paid by the biotech to the IP originator (for ex. university)?

What are the typical fees (percentages) to be paid to the licensor (for example a university) in case of an out-licensing (or sublicensing) a product (or a therapeutic indication with the product)? this depends obviously on the stage of development, but what are those numbers like at each stage? Also, is it a standard practice to have payment due at each fund raising?

3 Replies

Pat Conarro
0
0
Pat Conarro Entrepreneur
President/CEO/CTO at Colorado Wind
My technology compay MicroTool licence out 1 of 13 robotic calibration patents for $600K/year back in the late 90's. The payments were quarterly. We kept manufacturing the item and had no restrictions on where the licensor could sell. It was an awesome deal.
Thomas J. Kaled
1
0
Thomas J. Kaled Advisor
Business Development Consultant @ thomas.kaled@gmail.com
In short Mimoun fees are subject to negotiation and the value of the device, method, expertise or drug to the acquiring Biotech. If the University has taken the position of a principle, partner or limited partner will determine how they are treated at each phase of a venture. I have seen percentages of net profits or simply, equity or simply assumption of overhead and acquisition of equipment to be used by both the University and Biotech as a range of 'deal' structure.

JP Stoops
0
0
JP Stoops Advisor
Founder & CEO at Stealth Mode Startup Company
It depends on the volume, product category and quality of the license. Royalties payable on physical products can range between 8-15%. I can't tell if you're talking about drugs but items with high R&D or technical components can warrant lower royalties. Consumables also warrant lower royalties in the 2-4% range. I wouldn't see why payments would be tied to fund raising. They should be based on your forecast of sales over a 2-3 year period and paid quarterly.
Join FounderDating to participate in the discussion
Nothing gets posted to LinkedIn and your information will not be shared.

Just a few more details please.

DO: Start a discussion, share a resource, or ask a question related to entrepreneurship.
DON'T: Post about prohibited topics such as recruiting, cofounder wanted, check out my product
or feedback on the FD site (you can send this to us directly info@founderdating.com).
See the Community Code of Conduct for more details.

Title

Give your question or discussion topic a great title, make it catchy and succinct.

Details

Make sure what you're about to say is specific and relevant - you'll get better responses.

Topics

Tag your discussion so you get more relevant responses.

Question goes here

1,300 Followers

  • Name
    Details
  • Name
    Details
  • Name
    Details
  • Name
    Details
  • Name
    Details
  • Name
    Details
  • Name
    Details
  • Name
    Details
Know someone who should answer this question? Enter their email below
Stay current and follow these discussion topics?